Nexalin Technology signs 10-year South America distribution deal
Nexalin Technology (Nasdaq: NXL) has signed a definitive 10-year exclusive distribution and local manufacturing agreement with Inovanexa Medical Technologies S.A., covering Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador and Venezuela. The deal positions the Houston-based neurostimulation company to commercialise its Nexalin Sync device across a combined addressable population of more than 300 million people, with the company describing the arrangement as its transition from a pre-revenue R&D business toward a revenue-generating model.
The agreement formalises a letter of intent signed in February 2026 and includes a binding initial purchase order for ten Nexalin Sync devices at signing, five of which are to be delivered immediately. A clinical pilot programme in Brazil is targeted to launch within 90 days, funded by Inovanexa rather than Nexalin itself.
Deal structure and economics
The commercial framework is structured to be capital-light for Nexalin. Once Inovanexa has purchased the first 30 devices, it is contractually required to establish a local manufacturing facility in Brazil entirely at its own cost, operating under Nexalin's technical supervision. Nexalin will retain full ownership of all intellectual property and will supply the encrypted circuit boards central to each device, earning fixed per-device compensation and a per-unit royalty on every locally manufactured disposable electrode sold. The company says this is intended to create a recurring, usage-driven revenue stream without requiring Nexalin to deploy capital into the manufacturing buildout.
The structured pricing framework covers the initial 100-device commercialisation programme and includes a mechanism for larger transactions with government and private-sector customers, plus equal profit-sharing on qualifying private-sector deals involving Brazil-assembled devices.
Chief executive Mark White said the agreement represented "the inflection point Nexalin has been working toward," adding that the distributor-funded model allows the company to earn revenue on every device and consumable placed into the market while retaining full control of the underlying technology.
Market context and regulatory read-across
The Nexalin Sync device already holds approval from ANVISA, Brazil's national health regulator, for the treatment of anxiety, depression and insomnia. A single-site investigator-initiated trial at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo reported a 77.8% anxiety response rate, though the company's own disclosures note that these results may not be replicated in larger populations or commercial use. Nexalin is also pursuing an FDA De Novo pathway in the United States, where the device does not yet have marketing authorisation.
The neurostimulation sector for mental health indications is attracting growing interest, with transcranial magnetic stimulation and transcranial direct current stimulation devices already on the market from established players, and a number of smaller companies developing wearable and non-invasive alternatives targeting the same anxiety, depression and sleep-disorder space. Latin America is viewed as an underserved market for non-pharmacological mental health interventions, with reimbursement frameworks still underdeveloped across most of the seven countries covered by this agreement.
Near-term milestones to watch include the launch and readout of the 90-day clinical pilot, the placement of purchase orders beyond the initial binding ten-device commitment, and progress on the anticipated licensing and manufacturing agreement that must be separately negotiated before the Brazilian facility can be established. Nexalin's own risk disclosures make clear that revenue beyond the initial order is not guaranteed and depends substantially on Inovanexa meeting its performance obligations.